The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases - PubMed (original) (raw)

Review

doi: 10.1038/nri3823. Epub 2015 Apr 17.

Affiliations

Review

The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases

David Klatzmann et al. Nat Rev Immunol. 2015 May.

Abstract

Depletion of regulatory T (TReg) cells in otherwise healthy individuals leads to multi-organ autoimmune disease and inflammation. This indicates that in a normal immune system, there are self-specific effector T cells that are ready to attack normal tissue if they are not restrained by TReg cells. The data imply that there is a balance between effector T cells and TReg cells in health and suggest a therapeutic potential of TReg cells in diseases in which this balance is altered. Proof-of-concept clinical trials, now supported by robust mechanistic studies, have shown that low-dose interleukin-2 specifically expands and activates TReg cell populations and thus can control autoimmune diseases and inflammation.

PubMed Disclaimer

References

    1. Science. 2006 Mar 31;311(5769):1924-7 - PubMed
    1. Immunity. 2003 Oct;19(4):503-14 - PubMed
    1. Immunity. 2012 May 25;36(5):847-56 - PubMed
    1. J Immunol. 1985 Jan;134(1):157-66 - PubMed
    1. Proc Natl Acad Sci U S A. 2010 Jun 29;107(26):11906-11 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources